Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine

References

• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388:73–85.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
   PubMed Web of Science ®Google Scholar
• Malik NK, May KS, Chandrasekhar R, et al. Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. J Gastrointest Oncol. 2012;3:326–334.
   PubMedGoogle Scholar
• Barton-Burke M. Gemcitabine: a pharmacologic and clinical overview. Cancer Nurs. 1999;22:176–183.
   PubMed Web of Science ®Google Scholar
• Kim MP, Gallick GE. Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res. 2008;14:1284–1285.
   PubMed Web of Science ®Google Scholar
• de Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741:8–16.
   PubMed Web of Science ®Google Scholar
• O’Reilly EM. Pancreatic adenocarcinoma: new strategies for success. Gastrointest Cancer Res. 2009;3:S11–S15.
   Google Scholar
• Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011;378:607–620.
   PubMed Web of Science ®Google Scholar
• Schniewind B, Christgen M, Kurdow R, et al. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer. 2004;109:182–188.
   PubMed Web of Science ®Google Scholar
• Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009;136:187–195.
   PubMed Web of Science ®Google Scholar
• Greenhalf W, Ghaneh P, Neoptolemos JP, et al. European Study Group for Pancreatic C. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst. 2014;106:djt347.
   PubMed Web of Science ®Google Scholar
• Nordh S, Ansari D, Andersson R. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review. World J Gastroenterol. 2014;20:8482–8490.
   PubMed Web of Science ®Google Scholar
• Skrypek N, Duchene B, Hebbar M, et al. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Oncogene. 2013;32:1714–1723.
   PubMed Web of Science ®Google Scholar
• Marechal R, Mackey JR, Lai R, et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res. 2009;15:2913–2919.
   PubMed Web of Science ®Google Scholar
• Kaur S, Kumar S, Momi N, et al. Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol. 2013;10:607–620.
   PubMed Web of Science ®Google Scholar
• Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9:874–885.
   PubMed Web of Science ®Google Scholar
• Jonckheere N, Skrypek N, Van Seuningen I. Mucins and pancreatic cancer. Cancers (Basel). 2010;2:1794–1812.
   PubMedGoogle Scholar
• Andrianifahanana M, Moniaux N, Schmied BM, et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res. 2001;7:4033–4040.
   PubMed Web of Science ®Google Scholar
• Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008;70:431–457.
   PubMed Web of Science ®Google Scholar
• Terada T, Ohta T, Sasaki M, et al. Expression of MUC apomucins in normal pancreas and pancreatic tumours. J Pathol. 1996;180:160–165.
   PubMed Web of Science ®Google Scholar
• Yonezawa S, Sato E. Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int. 1997;47:813–830.
   PubMed Web of Science ®Google Scholar
• Bafna S, Kaur S, Momi N, et al. Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin. Br J Cancer. 2009;101:1155–1161.
   PubMed Web of Science ®Google Scholar
• Kalra AV, Campbell RB. Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain. Br J Cancer. 2007;97:910–918.
   PubMed Web of Science ®Google Scholar
• Kalra AV, Campbell RB. Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours. Eur J Cancer. 2009;45:164–173.
   PubMed Web of Science ®Google Scholar
• Mimeault M, Johansson SL, Senapati S, et al. MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies. Cancer Lett. 2010;295:69–84.
   PubMed Web of Science ®Google Scholar
• Wissniowski TT, Meister S, Hahn EG, et al. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells. Int J Oncol. 2012;40:1581–1589.
   PubMed Web of Science ®Google Scholar
• Ansari D, Urey C, Gundewar C, et al. Comparison of MUC4 expression in primary pancreatic cancer and paired lymph node metastases. Scand J Gastroenterol. 2013;48:1183–1187.
   PubMed Web of Science ®Google Scholar
• Aloysius MM, Zaitoun AM, Awad S, et al. Mucins and CD56 as markers of tumour invasion and prognosis in periampullary cancer. Br J Surg. 2010;97:1269–1278.
   PubMed Web of Science ®Google Scholar
• Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413.
   PubMed Web of Science ®Google Scholar
• Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–1481.
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–277.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–1081.
   PubMed Web of Science ®Google Scholar
• Constantinou PE, Danysh BP, Dharmaraj N, et al. Transmembrane mucins as novel therapeutic targets. Exp Rev Endocrinol Metab. 2011;6:835–848.
   PubMedGoogle Scholar
• Remmers N, Anderson JM, Linde EM, et al. Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer. Clin Cancer Res. 2013;19:1981–1993.
   PubMed Web of Science ®Google Scholar
• Chaturvedi P, Singh AP, Moniaux N, et al. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res. 2007;5:309–320.
   PubMed Web of Science ®Google Scholar